comscoreVerzenio Plus Faslodex Improves Survival in Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer, Regardless of Menopausal Status

Verzenio Plus Faslodex Improves Survival in Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer, Regardless of Menopausal Status

Dr. George Sledge discusses results from the MONARCH 2 study.
Oct 8, 2019
00:00
Download
00:00

At the European Society for Medical Oncology 2019 Congress, Dr. Sledge presented overall survival results from the MONARCH 2 study, which used Verzenio (chemical name: abemaciclib) and Faslodex (chemical name: fulvestrant) to treat metastatic hormone-receptor-positive, HER2-negative breast cancer that was previously treated with hormonal therapy and had stopped responding. The women in the study were premenopausal, perimenopausal, or postmenopausal.

Listen to the podcast to hear Dr. Sledge explain:

  • the background of the MONARCH 2 study

  • how much overall survival was improved

  • the side effects seen in the study

  • what the results mean for people diagnosed with metastatic hormone-receptor-positive, HER2-negative breast cancer

About the guest
 
george sledge headshot
George W. Sledge, MD

Affiliations: Stanford University Medical Center, Stanford Cancer Institute, Immix Biopharma

Areas of specialization: breast cancer, medical oncology, biologic
treatments for breast cancer

Dr. George Sledge is professor of medicine and head of the Oncology Division at Stanford University. A former president of the American Society of Clinical Oncology, he specializes in breast cancer research. He has published extensively on the treatment of metastatic breast cancer and has been honored with numerous awards for his work.



— Last updated on February 11, 2022, 7:58 PM

 
Lilly Oncology

This content made possible by Lilly Oncology.

 
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate